SCHEDULE: venBio Takes 9.99% Stake in Achieve Life Sciences

venBio Global Strategic Fund V, L.P. and its general partner have acquired a 9.99% beneficial ownership stake in Achieve Life Sciences, Inc. through a private placement, securing a board seat.

Summary

• Reporting Persons (venBio Global Strategic Fund V, L.P. and venBio Global Strategic GP V, LLC) acquired 10,737,317 shares of Achieve Life Sciences, Inc. common stock, representing approximately 9.99% of the outstanding shares.
• The acquisition was part of a private placement where Fund V purchased 5,914,720 shares of Common Stock and 5,914,720 Common Warrants for $21,500,007.20.
• The Common Warrants have an exercise price of $3.51 per share and their expiry is tied to FDA approval of cytisinicline for smoking cessation in adults.
• As part of the agreement, venBio secured the right to designate one director to the Issuer's Board, with Dr. Aaron Royston appointed effective April 17, 2026.
• The Issuer agreed to file a registration statement for the resale of the acquired securities within 30 days of the private placement closing and aim for effectiveness within 75 days.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development. A significant strategic investment from a specialized fund like venBio, accompanied by a board seat, indicates investor confidence and potential for enhanced strategic guidance, though the dilution from the private placement and regulatory contingencies for warrants introduce some caution.

Positives

• Strategic investment by a specialized life sciences fund (venBio) signals confidence in Achieve Life Sciences' future prospects and pipeline.
• venBio secured a board seat, allowing for direct influence and oversight, potentially aligning strategic direction and enhancing corporate governance.
• The private placement provides capital to Achieve Life Sciences, strengthening its financial position for ongoing operations and development.

Negatives

• The private placement involved the issuance of a significant number of new shares and warrants, which could lead to dilution for existing shareholders.
• The full exercisability of some warrants is contingent on FDA approval of cytisinicline, introducing a regulatory risk factor that could delay or prevent full value realization.

Risks

• The full exercise of Common Warrants is contingent on U.S. Food and Drug Administration (FDA) approval of cytisinicline for smoking cessation in adults, introducing regulatory uncertainty.
• If the Issuer has insufficient authorized and unreserved shares of Common Stock at the time of FDA approval, the Common Warrants' exercisability period extends, requiring stockholder approval for an amendment to increase authorized shares, which may not be obtained.
• Holders of Common Warrants or Pre-Funded Warrants are subject to an Ownership Limitation (e.g., 9.99% for Fund V) which restricts immediate full exercise, potentially limiting liquidity or control.

Future Outlook

The future outlook for Achieve Life Sciences, Inc. is closely tied to the potential FDA approval of cytisinicline for smoking cessation, which is a key condition for the full exercisability of a significant portion of the newly issued Common Warrants. The Issuer is also committed to filing a registration statement for the resale of the acquired securities within 30 days and aiming for effectiveness within 75 days, indicating a path for investors to monetize their holdings. venBio, as a significant shareholder with a board seat, may engage in discussions regarding the company's strategic direction and capitalization.

Management Comments

• The Issuer shall take all necessary action to cause its board of directors to comprise a total of eleven or fewer directors, one of whom shall be designated by venBio Partners LLC or any affiliates thereof.
• The Issuer also agreed to nominate the venBio Director for re-election to the Board at the 2026 annual meeting of stockholders and the 2027 annual meeting of stockholders, until such time as the Reporting Persons beneficially own less than 5% of the outstanding shares of Common Stock of the Issuer.

Industry Context

StockSavvy.ai notes that a significant investment by a specialized life sciences fund like venBio, coupled with securing a board seat, often signals a strong belief in the long-term potential of the company's pipeline or technology. This move could be interpreted as a vote of confidence in Achieve Life Sciences' cytisinicline program, especially given the warrant's expiry is tied to FDA approval. Such strategic investments are common in the biotech sector where capital infusion and expert guidance are crucial for drug development and commercialization.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• NA

Stakeholder Impact

• Shareholders: Potential dilution from the private placement, but also potential benefit from strategic investment and board oversight by a specialized life sciences fund.
• Management: Will work with a new board member (Dr. Royston) representing a significant investor, potentially influencing strategic decisions.
• Creditors: The capital raise could improve the company's financial stability, potentially benefiting creditors.

Next Steps

• Issuer to file a registration statement with the SEC within 30 days of the private placement closing for the resale of acquired securities.
• Issuer to use reasonable best efforts to have the registration statement declared effective within 75 days of its initial filing.
• Potential FDA approval of cytisinicline for smoking cessation, which impacts the exercisability of Common Warrants.
• Issuer to nominate the venBio Director for re-election at the 2026 and 2027 annual meetings of stockholders.
• Reporting Persons may engage in further discussions with the Board, management, or other stockholders regarding the Issuer's business, strategy, or capitalization.
• Reporting Persons may acquire or dispose of additional securities of the Issuer.

Key Dates

Recommendation

The significant investment by venBio and the appointment of a director to the board signal a vote of confidence in Achieve Life Sciences. However, the full value realization from the warrants is contingent on FDA approval of cytisinicline, which introduces regulatory risk. While the capital raise is positive, the associated dilution and the speculative nature of drug development suggest a 'hold' position until there is clearer progress on the regulatory front and the impact of the new board member's influence becomes more apparent.

Keywords

Achieve Life Sciences, venBio, Schedule 13D, Private Placement, Common Stock, Warrants, Board Appointment, Cytisinicline, FDA Approval, Life Sciences Investment, Strategic Investment, Corporate Governance